Formulary guidance and transparency from P&T to point of care

MMIT Reality Check on Hypertension (Oct 2018)

Posted by Matt Breese on Oct 26, 2018

Find me on:

According to our recent payer coverage analysis for hypertension treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape.

To help make sense of this new research, MMIT's team of experts analyzes the data and summarizes the key findings for you. The following are brief highlights. To read the full piece, including payer coverage, drug competition and prescriber trends, click here.

Payer Coverage: A review of market access for hypertension treatments shows that about 44% of the lives under commercial formularies are unrestricted. 

MMIT-Reality Check-Hypertension_4Q2018Data snapshot as of Q3 2018

Trends: With a wide variety of generic drugs available, brand name hypertension drugs are rarely prescribed to patients, and costs remain low. Via AIS Health.

To read the full Reality Check on Hypertension treatments with key findings on clinical characteristics, drug market access and payer coverage, please click on the button below: 


View Reality Check

Topics: Specialty, Market Access, Payer, Branding & Marketing